Nevertheless, it is possible that multiple factors associated with AD might contribute to the pathological misregulation of APP-Gαo signaling (including FAD-linked mutations in both APP and the presenilins), as well as the accumulation of neurotoxic amyloid peptides that can hyperactivate this pathway. This evidence concerns the gene APP and Alzheimer disease.